Compare Yomeishu Seizo Co., Ltd. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 2.04%
- The company has been able to generate a Return on Equity (avg) of 2.04% signifying low profitability per unit of shareholders funds
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 45.05
3
Poor long term growth as Net Sales has grown by an annual rate of -0.90% over the last 5 years
4
Flat results in Jun 25
5
With ROE of 1.53%, it has a expensive valuation with a 1.09 Price to Book Value
6
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
JPY 71,610 Million (Small Cap)
72.00
NA
0.00%
-0.16
1.74%
1.51
Revenue and Profits:
Net Sales:
2,341 Million
(Quarterly Results - Sep 2025)
Net Profit:
-3 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
64.45%
0%
64.45%
6 Months
71.96%
0%
71.96%
1 Year
93.79%
0%
93.79%
2 Years
137.01%
0%
137.01%
3 Years
148.0%
0%
148.0%
4 Years
133.69%
0%
133.69%
5 Years
129.49%
0%
129.49%
Yomeishu Seizo Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-0.90%
EBIT Growth (5y)
-26.52%
EBIT to Interest (avg)
45.05
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.12
Sales to Capital Employed (avg)
0.22
Tax Ratio
30.22%
Dividend Payout Ratio
91.69%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.90%
ROE (avg)
2.04%
Valuation key factors
Factor
Value
P/E Ratio
72
Industry P/E
Price to Book Value
1.09
EV to EBIT
348.37
EV to EBITDA
53.84
EV to Capital Employed
1.11
EV to Sales
4.46
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
0.32%
ROE (Latest)
1.53%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
2,341.40
2,341.20
0.01%
Operating Profit (PBDIT) excl Other Income
243.00
180.40
34.70%
Interest
0.00
6.30
-100.00%
Exceptional Items
-53.30
0.00
Consolidate Net Profit
-3.00
42.60
-107.04%
Operating Profit Margin (Excl OI)
16.10%
19.10%
-0.30%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 0.01% vs -5.49% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is -107.04% vs 233.54% in Sep 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
10,017.30
10,242.20
-2.20%
Operating Profit (PBDIT) excl Other Income
845.00
1,041.40
-18.86%
Interest
26.60
24.10
10.37%
Exceptional Items
-39.30
-0.00
Consolidate Net Profit
679.60
952.80
-28.67%
Operating Profit Margin (Excl OI)
12.80%
46.30%
-3.35%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is -2.20% vs -3.80% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is -28.67% vs -6.64% in Mar 2024
About Yomeishu Seizo Co., Ltd. 
Yomeishu Seizo Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






